NCT04863703View on ClinicalTrials.gov

Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)

Active, not recruitingOBSERVATIONAL
Enrollment

11

Participants

Timeline

Start Date

May 7, 2021

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2026

Conditions
Hepatitis DHepatitis BPortal HypertensionLiver Cirrhosis
Interventions
DRUG

Bulevirtide

Patients with liver cirrhosis and HBV/HDV coinfection receive Bulevirtide as an antiviral therapy irrespective of the study, this study is observational.

Trial Locations (1)

30625

Hannover Medical School, Hanover

All Listed Sponsors
lead

Hannover Medical School

OTHER